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abstract
A 83-year-old woman was admitted to hospital with 
chest pain, fever, dry cough and palpitations. Chest X-ray 
revealed a pleural effusion, assumed to be caused by car-
diac failure and respiratory infection. Despite treatment 
with antibiotics and diuretics, the pleural effusion 
increased on chest X-ray and there were signs of pleural 
and pericardial effusion on computed tomography (CT) 
scan. Treatment with non-steroidal anti-inflammatory 
drugs (NSAIDs) was not successful. Meanwhile patients’ 
long-term use of ergotamine for migraine was revealed, 
which is associated with pleuropulmonary and cardiac 
fibrotic reactions. Tentative treatment with colchicine 
was successful, with complete resolution of pleural fluid, 
fever, cough and inflammatory parameters. This case 
highlights the importance of establishing an ergot alka-
loid use registry in unexplained pleuropericardial effu-
sions and supports the use of colchicine as a potential 
therapeutic approach.
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casE rEport
A 83-year-old woman, previously in excellent medical 
condition, presented at the emergency department with 
complaints of severe retrosternal and interscapular pain, 
dry cough and palpitations since two days. She had a med-
ical history of curatively treated ovary and breast carci-
noma respectively 24 and 6 years ago and has suffered 
minor depressive symptoms for which she was taking citalo-
pram.
Clinical examination revealed an irregular tachycardia of 
130 beats per minute, bibasal lung crepitations and body 
temperature of 38.2°C. Blood analysis showed an elevated 
CRP (C-reactive protein) of 171 mg/L (normal reference 
< 5.0 mg/L). The heart was enlarged at chest X-ray, with lim-
ited bilateral pleural effusions, and a possible retrocardial 
pneumonia. The patient was treated for pneumonia with 
amoxicillin-clavulanate. A CT scan of the thorax confirmed 
bilateral pleural effusions, which were assumed to result from 
pneumonia and/or cardiac failure due to a new onset rapid 
atrial fibrillation. Initial cardiac ultrasound showed a normal 
cardiac function, but there was some thickening of the mitral 
valve. The patient was treated with loop diuretics and beta-
blockers followed by clinical improvement. Because pleural 
fluid on chest X-ray decreased with a parallel decrease in 
blood CRP to 27 mg/L, she was discharged from the hospital.
Two weeks later, the patient was re-admitted due to 
increasing dyspnea with fever up to 38.9°C and an elevated 
CRP level (213 mg/L). Chest X-ray revealed substantial bilat-
eral pleural effusions, which were initially treated as a recur-
rent respiratory infection, with secondary cardiac failure. 
Despite treatment with ceftriaxone and loop diuretics, fever 
continued and pleural effusions increased without any 
decrease in CRP levels. A new thoracic CT-scan revealed signs 
of pleuropericarditis: pleural and pericardial effusion, with 
contrast uptake in the pericardium. Pleural fluid analysis 
showed a protein content of 41 g/L and lactate dehydroge-
nase (LDH) of 280 U/L, compared to serum levels of 62 g/L 
and 319 U/L respectively, defining the fluid as exudate. As 
the patient had a history of malignancy, recurrence was 
excluded by fluorodeoxyglucose positron emission tomog-
raphy (FDG-PET) and absence of malignant cells on cytology 
examination of the pleural effusion. FDG-PET was also not 
compatible with possible other inflammatory diseases 
including giant cell arteritis. Serum titers for antinuclear anti-
bodies were absent. Screening for infectious agents includ-
ing bacterial blood –and sputum cultures and Mantoux test 
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7 days and we saw a rapid clinical and radiological remission. 
Magnetic resonance imaging (MRI) of the heart at that time 
showed a pericardial effusion without signs suggestive of 
constriction. The patient was discharged a week after starting 
the treatment with colchicine, in good overall condition.
Ambulatory follow-up 4 weeks after starting colchicine 
therapy was favourable, with normal clinical, biochemical and 
radiological findings on chest X-ray (see Figure 1). At that 
time the dose of colchicine was reduced to 0.5 mg daily. The 
patient remained symptom-free so that after another month, 
treatment with colchicine was stopped. Ambulatory evalua-
tion 2 months later showed no clinical or radiological signs of 
relapse.
discussion
Cafergot® is a combination drug, approved by the FDA in 
1960 to treat migraine headache. It contains both caffeine 
and ergotamine, the latter belonging to the family of the 
ergot alkaloids. Ergotamine causes vasoconstriction of vascu-
lar smooth muscle by partial agonist effects at α adreno-and 
vascular 5-HT (serotonin) receptors. The anti-migraine action 
of ergot alkaloids is thought to be egulated by serotonin 
receptors. Ergotamine modulates intra and extracranial blood 
flow leading to a decrease in the amplitude of pulsations of 
the cranial arteries, and to reduced hyperperfusion of the 
basilar artery territory (7). The drug is available in Belgium in 
tablets or rectal suppositories, combined with caffeine to 
enhance absorption.
We describe the case of a 83-year old woman who devel-
oped sudden pleuropericardial effusions associated with 
chronic use of low-dose ergotamine for migraine headache. 
The chronic use of ergot alkaloids is known to be associated 
were negative.  Serology for adenovirus, hepatitis virus, cyto-
megalovirus, human immunodeficiency virus and parvovirus 
proved also to be negative; repeated Coxsackie virus serol-
ogy could not reveal a recent infection either. There was no 
history of exposure to asbestos. Although the causative 
agent was unknown, treatment with NSAIDs was initiated 
with ibuprofen 600 mg three times daily. Hereunder, CRP lev-
els decreased from 90 mg/L to 42 mg/L after five days. Chest 
X-ray also showed some reduction in pleural effusions and 
the patient was discharged from the hospital. Five days later 
she represented at the emergency department with recur-
rent dyspnea and fever. CRP was elevated to 96 mg/L. Chest 
X-ray (Figure 1) showed an increase in pleural fluid. Pleuros-
copy was performed to exclude pleural malignancy: bioptic 
and cytologic examination showed granulation tissue and 
numerous macrophages as signs of clearance response. A 
temporary thoracic drain was inserted.
Because the causative agent remained unclear, a renewed 
history was taken. The patient now mentioned her regular 
and prolonged use of ergotamine and caffeine (Cafergot®) 
because of a recurrent migraine that had not reappeared 
since her initial admission. She did not consider this as being 
relevant since she only took a very small dose (about a quar-
ter, i.e.. 0.25-0.50 mg ergotamine) via suppository daily, how-
ever she took this for almost 50 years. Initially, her usage of 
ergotamine was discontinuous with regular drug-free epi-
sodes of maximally two weeks. The last 5 years, ergotamine 
was taken on daily basis.
The standard treatment for ergot-induced pleuropericar-
ditis is to discontinue the intake of the provoking drug but in 
this case, symptoms did not resolve after several weeks and 
the patient relapsed twice. Therefore, we initiated a therapy 
with colchicine at 1 mg daily. Under this therapy, CRP 
decreased from 38 mg/L to a normal value (< 5 mg/L) in 
figure 1: patients’ chest X-ray. 
left: at third admission in hospital. right: 4 weeks after treatment with colchicine.
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Because colchicine accumulates in leucocytes, an ade-
quate response can be reached at low oral doses. The main-
tenance dose for acute pericarditis is usually 1 mg a day, 
divided into 2 gifts for three months. Pain relief is achieved 
within 12-24 hours if adequately dosed. Under this therapy, 
our patient showed rapid clinical, biochemical and radiologi-
cal improvement.
conclusion
Causes of pleuritis/pericarditis can be uncommon and 
require several investigations. This case highlights the impor-
tance of preceding ergot alkaloid use registry in unexplained 
pleuropericardial effusions. Chronic use of this drug class 
should be discouraged. To our knowledge, this is the first 
report of ergotamine-induced pleuropericarditis successfully 
treated with low dose colchicine.
conflict of intErEsts: None.
rEfErEncEs
1. Allen MB, Tosch G. Pleural and pericardial fibrosis after ergotamine therapy. res-
piratory medicine 1994; 88, 67-69.
2. Smith SA. Role of serotoninergic pathways in drug-induced valvular heart dis-
ease and diagnostic features by echocardiography. J A soc Echocardiogr 2009; 22: 
883-889.
3. Naranjo CA. A method for estimating the probability of adverse drug reactions. 
Clin pharmacol ther 1981; 30: 239-245.
4. Köningshoff M, Rio dimitrascu. Increased expression of 5-hydroxytryptamine2A/B 
receptors in idiopathic lung fibrosis: a rationale for therapeutic intervention. tho-
rax 2010; 65: 949-955.
5. Imazio M, Brucato A. Colchicine for pericarditis: hype or hope? European heart 
journal 2009; 30: 532-539.
6. Terkeltaub R. Colchicine update. semin Arthritis and rheum 2009; 38: 411-419.
7. Drug Bank Available at: http://www.drugbank.ca/drugs/DB00696 (Accessed 
25 April 2012).
with connective tissue proliferation in the retroperitoneal 
space, the pleural cavity and pericardial/endocardial tissues, 
which can lead to cardiac murmur or valvular damage (1, 2, 
5). For this reason methysergide, an amine ergot alkaloid, 
was withdrawn in the USA, while it is still available in Bel-
gium.
The event scored 7 points on the Naranjo scale3, a scale 
developed to assess the likelihood and causality of adverse 
drug events. A Naranjo score between 5 and 8 rates the event 
as “probably” due to chronic treatment with ergotamine.
The exact mechanism which causes the fibrotic reactions 
is a matter of debate, but serotonin-induced fibrosis is one 
possible explanation through its action on 5-HT2b receptors. 
A recent study confirmed the increased expression of 
5-HT2a/b receptors in idiopathic lung fibrosis with decreased 
fibrotic reaction and improved lung function after the admin-
istration of terguride, a 5-HT2a/b antagonist, hereby support-
ing the evidence for a dominant role of serotonin in this dis-
ease (4).
Because symptoms initially progressed after drug discon-
tinuation, additional treatment with NSAIDs was initiated. 
However, the disease relapsed under treatment with ibupro-
fen and therefore therapy with colchicine was initiated based 
on recent studies promoting colchicine as the agent of choice 
for treatment of pericarditis, even in first line (5). Its combined 
anti-inflammatory properties seem very attractive in the 
treatment of our patient’s condition, believed to be acting 
through β-tubulin binding, a component of the cell cytoskel-
eton, indispensable for a variety of cellular motility functions 
including chemotaxis, phagocytosis and degranulation. Bind-
ing to β-tubulin blocks the dynamic formation of microtu-
bules causing decreased mobility of leucocytes and phago-
cytes, thereby decreasing inflammatory reactions. Besides 
β-tubulin binding, several other cardinal mechanisms of 
action have been described, including the inhibition of IL-1 
production (6).
